Radiologic assessment of response to therapy: Comparison of recist versions 1.1 and 1.0

Hamid Chalian, Hüseyin Gürkan Töre, Jeanne M Horowitz, Riad Salem, Frank H Miller, Vahid Yaghmai*

*Corresponding author for this work

Research output: Contribution to journalArticle

50 Scopus citations

Abstract

Improvements in radiologic imaging technology and therapeutic options available for management of tumors have necessitated the revision of guidelines for the imaging-based assessment of tumor response to therapy. The purpose of this article is to familiarize radiologists with the modifications to the Response Evaluation Criteria in Solid Tumors (RE-CIST) that have been incorporated in the latest version of the guidelines, RECIST 1.1. The most important differences between this version and the previous one, RECIST 1.0, include reductions in the maximum number of lesions per patient and per organ that may be targeted for measurement, augmentation of the criteria defining progressive disease, additional guidelines for reporting findings of lesions that are too small to measure and for measuring lesions that appear to have fragmented or coalesced at follow-up imaging, new criteria for characterizing lymph-adenopathy, new criteria for selecting bone lesions and cystic lesions as targets for measurement, and the inclusion of findings at positron emission tomography among the indicators of disease response.

Original languageEnglish (US)
Pages (from-to)2093-2106
Number of pages14
JournalRadiographics
Volume31
Issue number7
DOIs
StatePublished - Dec 1 2011

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Radiologic assessment of response to therapy: Comparison of recist versions 1.1 and 1.0'. Together they form a unique fingerprint.

  • Cite this